Carisma Therapeutics Inc. reported a net loss of $9.266 million for Q1 2025, an improvement from a net loss of $18.978 million in Q1 2024. Collaboration revenues increased slightly to $3.729 million from $3.397 million in the prior year. The company's total operating expenses significantly decreased to $13.063 million from $22.907 million, primarily due to reductions in research and development and general and administrative expenses.

Carisma Therapeutics experienced a net loss of $60.477 million in Q4 2024, an improvement from the $86.879 million loss in the prior year. Collaboration revenues increased to $19.632 million, driven by a development candidate nomination. The company implemented significant workforce reductions and ceased development of certain product candidates as part of its cash preservation plan, leading to decreased operating expenses.

Carisma Therapeutics reported its Q3 2024 financial results, with a focus on advancing its clinical and preclinical programs, including the anticipated initial data from the Phase 1 study of CT-0525 in Q1 2025 and the nomination of a development candidate for the liver fibrosis program also expected in Q1 2025. The company's cash and cash equivalents are expected to fund operations into the third quarter of 2025.

Carisma Therapeutics reported that cash and cash equivalents are expected to fund the Company into the third quarter of 2025. Initial data for CT-0525, lead product candidate for anti-HER2 program, expected by year-end 2024. Nomination of a development candidate for liver fibrosis program expected in the first quarter of 2025.

Carisma Therapeutics reported their Q1 2024 financial results, focusing on the development of CT-0525 and CT-0508, and presented preclinical data in liver fibrosis. The company's cash and cash equivalents are expected to fund operations into the third quarter of 2025.

Carisma Therapeutics reported its Q4 and full year 2023 financial results, highlighting the prioritization of CT-0525 and a restructuring plan to extend its cash runway into Q3 2025. The company is focusing on its ex vivo and in vivo oncology programs, as well as research programs including fibrosis.

Carisma Therapeutics reported its Q3 2023 financial results, highlighting advancements in clinical and pre-clinical programs, including data from the Phase 1 clinical study of CT-0508 and pre-clinical work with Moderna. The company's cash, cash equivalents, and marketable securities are expected to fund operations into the first quarter of 2025.

Carisma Therapeutics reported its Q2 2023 financial results, highlighting the dosing of the first patient in the Phase 1 clinical trial of CT-0508 in combination with KEYTRUDA® and the nomination of an additional oncology target as part of the collaboration with Moderna. The company's cash, cash equivalents, and marketable securities of $117.1 million are expected to fund operations through 2024.

Carisma Therapeutics closed its merger with Sesen Bio and is focused on advancing its pipeline, with multiple potential value inflection points on the horizon, including the completion of the Phase 1 clinical trial of CT-0508 and upcoming data from the clinical trial sub-study of CT-0508 in combination with KEYTRUDA®.